

**BALLOON SINUS OSTIAL DILATION FOR CHRONIC
SINUSITIS AND EUSTACHIAN TUBE DILATION****Effective Date:** September 1, 2024**Review Dates:** 12/11, 12/12, 2/13, 2/14, 2/15, 2/16,
2/17, 2/18, 2/19, 2/20, 2/21, 2/22, 2/23, 2/24, 5/24**Date Of Origin:** December 14, 2011**Status:** Current**Summary of Changes**

Priority Health has contracted with [TurningPoint Healthcare Solutions LLC](#) for management of procedures within the scope of this policy. CPT procedure *C2625 Stent, noncoronary, temporary, with delivery system*, currently not covered, will now be managed by TurningPoint Healthcare Solutions LLC.

I. POLICY/CRITERIA

- A. The use of balloon sinus ostial dilation, e.g., Balloon Sinuplasty™, for the treatment of chronic sinusitis is considered medically necessary when all of the following criteria are met:
1. Documentation of persistent rhinosinusitis for greater than three months;
AND
 2. Documented failure of medical therapy greater than three months in duration demonstrated by persistent upper respiratory symptoms despite therapy consisting of a minimum of two different antibiotics with a trial of steroid spray, antihistamine spray and/or decongestant; **AND**
 3. Radiological evidence of at least ONE of the following:
 - i. Air fluid levels; OR
 - ii. Mucosal thickening > 2mm; OR
 - iii. Opacification; OR
 - iv. Nasal polypsis
- B. The use of devices (e.g., the Propel™ sinus implant, the Relieva Stratus™ MicroFlow spacer, and the Sinu-Foam™ spacer) for maintaining sinus ostial patency following balloon sinus ostial dilation and / or endoscopic sinus surgery is **experimental and investigational** because their effectiveness has not been established.
- Balloon sinus ostial dilation used as an adjunct during functional endoscopic sinus surgery (FESS) is considered integral to the primary FESS procedure and not separately reimbursable.**
- C. Nasopharyngoscopy, surgical, with dilation of eustachian tube (Eustachian tube balloon dilation)

1. Medical Necessity Criteria:

Unilateral or bilateral **Eustachian tube balloon dilation (ETBD)** is considered medically necessary once per lifetime for the treatment of **chronic obstructive Eustachian tube dysfunction** when ALL of the following criteria are met:

- Age 18 years or older
- Any of the following symptoms continuously for at least six months:
 - aural fullness (clogged ear sensation)
 - aural pressure or otalgia
 - hearing loss
 - autophony

Note: standardized patient reported questionnaire (ETDQ-7) recommended.

- History of chronic ear disease or intolerance to barometric changes greater than six months
- Tympanic membrane abnormality (i.e., retracted membrane, effusion) on exam
- Complete nasal endoscopy assessing the **Eustachian tube (ET)** lumen confirming transnasal access to the nasopharynx and eliminating extrinsic causes of **Eustachian tube dysfunction (ETD)**
- Failure, intolerance or contraindication to appropriate medical management of co-occurring conditions (rhinosinusitis, allergic rhinitis, laryngopharyngeal reflux)
- Tympanometry of intact tympanic membrane showing either:
 - Type A tympanogram (only provided that symptom relief occurred with prior myringotomy and tympanostomy tubes),
OR
 - Type B or Type C tympanogram
- If history of prior tympanostomy tube placement, relief from classic Eustachian tube obstructive symptom must be demonstrated while tubes were patent

Eustachian tube balloon dilation (ETBD) is considered **experimental, investigational, or unproven** for all other indications.

2. Exclusions: The following patients should not be considered for balloon dilatation of the Eustachian Tube:

- Patulous ETD (demonstrated by autophony of voice, pulsatile tinnitus, and/or aural fullness, visible respiratory variation of tympanic membrane (TM))
- Reversible or irreversible causes of the eustachian tube dysfunction including but not limited to:
 - Neoplasm, enlarged adenoids, or nasopharyngeal mass resulting in extrinsic compression
 - Congenital Craniofacial syndromes (eg. cleft)
 - Chronic degenerative neuromuscular conditions resulting in adynamic eustachian tube
 - Active systemic mucosal or autoimmune inflammatory conditions affecting nasal mucosa
 - Tobacco use
- Superior semicircular canal dehiscence
- Previous balloon dilation procedure

Patients undergoing BDET **concurrent with sinus ostial dilation or myringotomy** should meet the same diagnostic criteria for BDET as those undergoing BDET alone.

II. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, services, and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, or procedure is medically necessary. For more information, please refer to the [Priority Health Provider Manual](#).

III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- ❖ **POS:** *This policy applies to insured POS plans.*
- ❖ **PPO:** *This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.*

- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:** *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS) and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.*
- ❖ **MEDICAID/HEALTHY MICHIGAN PLAN:** *For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.*

IV. DESCRIPTION

Chronic sinusitis is defined as a prolonged or recurrent infection and inflammation of the nasal sinuses. Chronic, long-term sinusitis may develop in people with chronic allergies, deviated nasal septum or other obstruction of the nose. Additionally, dental infections such as tooth abscesses may also spread into the sinus and infect it directly.

A technique referred to as balloon sinus ostial dilation or Balloon Sinuplasty™ has been proposed as an alternative or in addition to standard endoscopic surgery. This procedure proposes the use of a small balloon-like device instead of the other devices usually used. There are two different devices available on the market that dilate the sinuses. With the first type of device, the balloon is placed in the blocked sinus passage under endoscopic guidance through the nostril. The second is placed in the sinus through an incision made in the gums and maxillary bone under the front lip of the individual. In both cases, once the balloon is in place in the ostia of the targeted sinus, the balloon is inflated to push the sinus tissue and bone out of the way, creating a larger airway passage and allowing drainage of nasal secretions.

Results of the available studies provide preliminary evidence that balloon sinus ostial dilation is relatively safe and efficacious for the treatment of chronic sinusitis that is refractory to medical therapy. Despite these promising early findings, the overall quality of the evidence is low since the majority of the available studies lack controls and adequate follow-up of the majority of the enrolled patients. The patient selection criteria for this therapy have not been well defined. Furthermore, many of the studies evaluated hybrid procedures, which creates difficulties in determining the specific role of balloon sinus ostial dilation in treatment outcomes. Additional studies are needed to confirm that balloon sinus

ostial dilation is safer and more effective over the long term than FESS or adenoidectomy, particularly well-designed trials that randomize patients to balloon sinus ostial dilation or to standard treatment for chronic sinusitis.

Eustachian tube dysfunction (ETD) is a physiological disorder of the **eustachian tube (ET)** that results in the inability to appropriately equalize pressure between the middle ear and the environment. Pressure equalization and ventilation of the middle ear is a primary function of the ET; other functions include mucociliary clearance of secretions from the middle ear and protection of the middle ear from pathogens, material, and sounds from the nasopharynx. ETD ranges from obstructive dysfunction, in which there is failure of the Eustachian tube (ET) to open and provide adequate ventilation to the middle ear, to patulous ETD in which there is failure of the ET to close. Patients may move back and forth on this spectrum, creating difficulties in diagnosis and appropriate treatment. The choice of management strategies for isolated Eustachian tube dysfunction should be directed at the underlying etiology, if known. The usual treatments for obstructive Eustachian tube dysfunction include medical management (decongestants, systemic and topical nasal steroids, or antihistamines) and pressure equalization methods (insufflation, tympanostomy, or balloon dilation of the eustachian tube. The Eustachian tube balloon dilation system is a device that includes a flexible catheter attached to an inflatable balloon. The system is intended for use in dilating the cartilaginous portion of the Eustachian tube to improve ET function.

Tympanometry measures the changes in the acoustic impedance of the middle ear system in response to changes in air pressure. As the pressure increases, the tympanic membrane is pushed medially; as negative pressure is placed, the tympanic membrane protrudes laterally. The point of maximum compliance of the middle ear is identified, indicating the status of air pressure in the middle ear.

Five types of tympanograms can be seen

- Type A – Normal middle ear pressure
- Type B – Little or no mobility, suggestive of fluid behind the tympanic membrane or perforation
- Type C – Negative pressure in the middle ear, suggestive of a retracted tympanic membrane
- Type A_S – A very stiff middle ear system that can be caused by myringosclerosis or otosclerosis
- Type A_D – The highly compliant tympanic membrane seen in ossicular chain discontinuity

American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS):
The AAO-HNS (2019) developed a clinical consensus statement on balloon

dilation of the Eustachian tube (ET). Eustachian tube balloon dilation was defined as “inserting a catheter with a balloon temporarily into the cartilaginous portion of the ET and then inflating the balloon to alleviate obstructive ETD.” Based on a systematic review of the literature and expert consensus, the Society’s statements included the following:

- “A comprehensive history and physical exam, including otoscopy, are essential parts of the diagnostic evaluation of a candidate for BDET
- Patient-reported symptom scores are useful in assessing baseline ETD symptoms and treatment outcomes.
- Patient-reported symptom scores alone are insufficient to establish a diagnosis of obstructive ETD.
- Nasal endoscopy is necessary to rule out extrinsic causes of ETD.
- Tympanometry and Comprehensive audiometry is an essential part of the diagnostic evaluation prior to BDET.
- BDET is contraindicated for patients diagnosed as having a patulous ETD (as suggested by symptoms of autophony of voice, audible respirations, pulsatile tinnitus, and/or aural fullness).
- The benefit of repeat BDET after a prior ineffective BDET has not been determined.
- BDET is an alternative to tympanostomy tube placement for obstructive ETD.

The seven-item Eustachian Tube Dysfunction Questionnaire (ETDQ-7) is a disease-specific instrument to assess symptoms with respect to ETD.

IV. CODING INFORMATION

ICD-10 Codes that may apply:

J32.0	Chronic maxillary sinusitis
J32.1	Chronic frontal sinusitis
J32.2	Chronic ethmoidal sinusitis
J32.3	Chronic sphenoidal sinusitis
J32.4	Chronic pansinusitis
J32.8	Other chronic sinusitis
J32.9	Chronic sinusitis, unspecified

CPT/HCPCS Codes:

31295	Nasal/sinus endoscopy, surgical; with dilation of maxillary sinus ostium (e.g., balloon dilation), transnasal or via canine fossa
31296	Nasal/sinus endoscopy, surgical; with dilation of frontal sinus ostium (e.g., balloon dilation)
31297	Nasal/sinus endoscopy, surgical; with dilation of sphenoid sinus ostium (e.g., balloon dilation)
31298	Nasal/sinus endoscopy, surgical; with dilation of frontal and sphenoid sinus ostia (e.g., balloon dilation)

- 69705 Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral
- 69706 Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral
- J7402 Mometasone furoate sinus implant, (Sinuva), 10 mcg (*covered only for Medicare. Prior authorization required*)

Not Covered:

- S1091 Stent, noncoronary, temporary, with delivery system (Propel)

V. REFERENCES

1. Ahmed J, Pal S, Hopkins C, Jayaraj S. Functional endoscopic balloon dilation of sinus ostia for chronic rhinosinusitis. *Cochrane Database Syst Rev*. 2011 ;(7):CD008515.
2. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). [Position Statement: Dilation of sinuses, any method \(e.g., balloon, etc.\)](#). April 21, 2021.
3. American Rhinologic Society (ARS). American Rhinologic Society (ARS) Revised Position Statement on Endoscopic Balloon Catheter Sinus Dilation Technology. 2017 revision.
4. American Rhinologic Society. [Balloon Dilation Clinical Consensus Statement](#).
5. American Rhinologic Society (ARS). [ARS Position Statement: Criteria for Sinus-ostial Dilation](#). January 28, 2023.
6. Bolger WE, Brown CL, Church CA, et al. Safety and outcomes of balloon catheter sinusotomy: a multicenter 24-week analysis in 115 patients. *Otolaryngol Head Neck Surg*. 2007; 137(1):10-20.
7. Centers for Medicare & Medicaid Services (CMS). Medicare Coverage Database. Advanced Search: National Coverage Documents [search: *sinuplasty*]. Updated August 8, 2011. Available at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>
8. Chandra RK. Estimate of radiation dose to the lens in balloon sinuplasty. *Otolaryngol Head Neck Surg*. 2007; 137(6):953-955.
9. Church CA, Kuhn FA, Mikhail J, Vaughan WC, Weiss RL. Patient and surgeon radiation exposure in balloon catheter sinus ostial dilation. *Otolaryngol Head Neck Surg*. 2008; 138(2):187-191.
10. Cigna. Medical Coverage Policy Number 0480. [Balloon Sinus Ostial Dilation for Chronic Sinusitis and Eustachian Tube Dilation](#).
11. Cigna. Medical Coverage Policy Number 0481. [Drug-Eluting Devices for Use Following Endoscopic Sinus Surgery](#).

12. Egan ME. Credentialing Resource Center (CRC). Otolaryngology. Clin Privil White Pap. 2010 ;(150):1-28. Balloon Therapy. May 22, 2006. Forbes.com [website]. Available at: <http://www.forbes.com/forbes/2006/0522/080.html>.
13. Entellus Medical. Entellus Medical Settles Patent Dispute [news release]. February 17, 2011. Available at: <http://www.entellusmedical.com/sites/default/files/u1/Press%20Release%20Entellus%20Medical%20Settles%20Patent%20Dispute.pdf>.
14. Friedman M, Schalch P, Lin HC, Mazloom N, Neidich M, Joseph NJ. Functional endoscopic dilatation of the sinuses: patient satisfaction, postoperative pain, and cost. *Am J Rhinol*. 2008; 22(2):204-209.
15. Hayes Inc., Propel Bioabsorbable Steroid-Releasing Sinus Implant. Prognosis Overview. Archived August 24, 2017 (advanced to Health Technology Brief).
16. Hayes, Inc. Balloon Sinuplasty for Treatment of Chronic Sinusitis, March 10, 2016.
17. Hayes, Inc. Propel and Propel Mini Bioabsorbable Steroid-Releasing Sinus Implants for Treatment of Chronic Rhinosinusitis in Adults. Published August 24, 2017. Annual Review August 14, 2018.
18. Heimgartner S, Eckardt J, Simmen D, Briner HR, Leunig A, Caversaccio MD. Limitations of balloon sinuplasty in frontal sinus surgery. *Eur Arch Otorhinolaryngol*. 2011 May 11. [Epub ahead of print]. Available at: <http://www.springerlink.com/content/hh778262h7247435>.
19. Hopkins C, Noon E, Bray D, Roberts D. Balloon sinuplasty: our first year. *J Laryngol Otol*. 2011; 125(1):43-52.
20. Jerger J. Clinical experience with impedance audiometry. *Arch Otolaryngol* 1970; 92:311.
21. Kaszuba SM, Stewart MG. Medical management and diagnosis of chronic rhinosinusitis: A survey of treatment patterns by United States otolaryngologists. *Am J Rhinol*. 2006; 20(2):186-190.
22. Kuhn FA, Church CA, Goldberg AN, et al. Balloon catheter sinusotomy: one-year follow-up--outcomes and role in functional endoscopic sinus surgery. *Otolaryngol Head Neck Surg*. 2008; 139(3 Suppl 3):S27-S37.
23. Kutluhan A, Bozdemir K, Cetin H, et al. Endoscopic balloon dilation sinuplasty including ethmoidal air cells in chronic rhinosinusitis. *Ann Otol Rhinol Laryngol*. 2009; 118(12):881-886.
24. Levine HL, Sertich AP 2nd, Hoisington DR, Weiss RL, Pritikin J; PatiENT Registry Study Group. Multicenter registry of balloon catheter sinusotomy outcomes for 1,036 patients. *Ann Otol Rhinol Laryngol*. 2008; 117(4):263-270.
25. Luukkainen V, Kivekäs I, Silvola J, Jero J, Sinkkonen ST. Balloon Eustachian Tuboplasty: Systematic Review of Long-term Outcomes and Proposed Indications. *J Int Adv Otol*. 2018 Apr;14(1):112-126.
26. Piccirillo, J. F., Payne, S. C., Rosenfeld, R. M., Baroody, F. M., Batra, P. S., DelGaudio, J. M., ... Corrigan, M. D. (2018). Clinical Consensus Statement: Balloon Dilation of the Sinuses. *Otolaryngology–Head and Neck Surgery*, 158(2), 203–214. <https://doi.org/10.1177/0194599817750086>

27. McCoul ED, Anand VK, Christos PJ. Validating the clinical assessment of eustachian tube dysfunction: The Eustachian Tube Dysfunction Questionnaire (ETDQ-7). *Laryngoscope*. 2012;122(5):1137-1141. doi:10.1002/lary.23223.
28. Poe D, Hanna B. Eustachian tube dysfunction. In: UpToDate, Kunins L (Ed). Last updated Oct 10, 2019. Waltham, MA. Accessed Dec 7, 2021.
29. Ramadan HH. Safety and feasibility of balloon sinuplasty for treatment of chronic rhinosinusitis in children. *Ann Otol Rhinol Laryngol*. 2009; 118(3):161-165.
30. Ramadan HH, McLaughlin K, Josephson G, Rimell F, Bent J, Parikh SR. Balloon catheter sinuplasty in young children. *Am J Rhinol Allergy*. 2010; 24(1):e54-e56.
31. Ramadan HH, Terrell AM. Balloon catheter sinuplasty and adenoidectomy in children with chronic rhinosinusitis. *Ann Otol Rhinol Laryngol*. 2010; 119(9):578-582.
32. Schilder, AG, Bhutta, MF, Butler, CC. Eustachian tube dysfunction: consensus statement on definition, types, clinical presentation and diagnosis. *Clin Otolaryngol*. 2015;40:407-411.
33. Stewart AE, Vaughan WC. Balloon sinuplasty versus surgical management of chronic rhinosinusitis. *Curr Allergy Asthma Rep*. 2010; 10(3):181-187.
34. Tucci DL, McCoul ED, Rosenfeld RM, et al. Clinical Consensus Statement: Balloon Dilation of the Eustachian Tube. *Otolaryngol Head Neck Surg*. Jul 2019; 161(1): 6-17. PMID 31161864.
35. Vaughan WC. Review of balloon sinuplasty. *Curr Opin Otolaryngol Head Neck Surg*. 2008; 16(1):2-9.
36. Weiss RL, Church CA, Kuhn FA, Levine HL, Sillers MJ, Vaughan WC. Long-term outcome analysis of balloon catheter sinusotomy: two-year follow-up. *Otolaryngol Head Neck Surg*. 2008; 139 (3 Suppl 3):S38-S46.

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.